ALT
Altimmune, Inc. Health Care Pharmaceutical Preparations Russell 3000
$2.04Close
$226.2MMarket cap
$2.04 – $6.1852-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 4 · weaker than 96% of stocks over 12 months
- Far from its high 67% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
67%
1wk
down 3.8%
price change
1mo
down 28.7%
price change
12-month return
down 50%
market up 11% ·
its own down 60%
F-score
—
— Not assessed
Altman Z
-0.77
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.0×
price / book
Earnings yield
down 43.6%
EBIT / enterprise value
Cheaper than
32%
of the market · expensive
Revenue growth
up 105%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 51%
return on equity
Free cash margin
down 164746%
-$67.5M FCF
D/E
0.15
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-95% then +105%)
Trade setup
ATR%
6.0%
$0.12 a day · 2×ATR $1.80
RS
4 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.73
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 53.3% over the year, from 72m to 111m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 12, 2026
Results reaction
Aug 12, 2026-5% vs market2 sessions after results
Financials
- Net -214861%
- Free cash -164746%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.2M | $4.4M | -$68,000 | $426,000 | $20,000 | $41,000 |
| Operating income | -$54.8M | -$96.9M | -$87.7M | -$95.9M | -$103.2M | -$94.5M |
| Net income | -$49.0M | -$97.1M | -$84.7M | -$88.4M | -$95.1M | -$88.1M |
| Net margin | -599% | -2201% | 124578% | -20762% | -475295% | -214861% |
| Earnings per share | -$1.91 | -$2.35 | -$1.81 | -$1.66 | -$1.34 | -$1.00 |
| Free cash flow | -$34.5M | -$90.4M | -$62.7M | -$75.9M | -$79.8M | -$67.5M |
| Free cash margin | -422% | -2049% | 92224% | -17807% | -399240% | -164746% |
| Cash | $115.9M | $190.3M | $111.1M | $135.1M | $36.9M | $43.8M |
| Long-term debt | $1.8M | $1.5M | $4.6M | — | — | $34.3M |
| Shareholders' equity | $225.9M | $199.1M | $185.3M | $194.1M | $123.5M | $224.9M |
| Shares outstanding | 37.14m | 40.99m | 49.20m | 70.68m | 72.35m | 110.88m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 12, 2026 | Quarterly ↗ | Jun 30, 2026 | 43d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 6, 2026 | Annual ↗ | Dec 31, 2025 | 65d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 27, 2024 | Annual ↗ | Dec 31, 2023 | 87d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | New obligation ↗ |
| Oct 27, 2026 | Director or officer change · Regulation FD ↗ |
| Sep 29, 2026 | Director or officer change ↗ |
| Aug 12, 2026 | Results ↗ |
| Jul 28, 2026 | Regulation FD · Other events ↗ |
| Jun 16, 2026 | Other events ↗ |
| May 13, 2026 | Results ↗ |
| Apr 24, 2026 | Material agreement ↗ |
| Apr 16, 2026 | Charter or bylaws · Shareholder vote ↗ |
| Mar 5, 2026 | Results ↗ |
| Feb 3, 2026 | Other events ↗ |
| Jan 28, 2026 | Material agreement ↗ |